RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock"As I have said many times, we have the best bug, given safety, ease of use and composition of matter patents for a wild virus."
however, as matt said in his video interview last year, when the fda requested that oncy move from using mouse tissue in the production of pela to using human tissue, they also requested that oncy sequence the reovirus genome produced from the human tissue culture.
to matt's surprise, the prior "wild" virus showed 12 points of genome change from the "wild" virus previously used in the mouse tissue cutures. the fda commented/encouraged matt to apply for patent protection for this "new" virus which is how oncy has patent protection until 2028 for its proprietary manufacturing technique with a 5 year extension possible after 2028.
that type of protection would certainly help with current patent cliffs bp is anticipating with their own products.
one of my concerns is any type of information sharing oncy has done with adlai nortye and if they/china could just thumb their noses as oncy if/when they get any type of chinese approval for the rollout of any pela combinations over there.
theft of trade secrets is certainly a concern of any company doing business in china.